Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
- Published In:
- EBioMedicine, 26, 78-90 (2017)
- Authors:
- Daveson, A James M, Ee, Hooi C, Andrews, Jane M, King, Timothy, Goldstein, Kaela E, Dzuris, John L, MacDougall, James A, Williams, Leslie J, Treohan, Anita, Cooreman, Michael P, Anderson, Robert P
- Database ID:
- RPEP-03262
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03262APA
Daveson, A James M; Ee, Hooi C; Andrews, Jane M; King, Timothy; Goldstein, Kaela E; Dzuris, John L; MacDougall, James A; Williams, Leslie J; Treohan, Anita; Cooreman, Michael P; Anderson, Robert P. (2017). Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.. EBioMedicine, 26, 78-90. https://doi.org/10.1016/j.ebiom.2017.11.018
MLA
Daveson, A James M, et al. "Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.." EBioMedicine, 2017. https://doi.org/10.1016/j.ebiom.2017.11.018
RethinkPeptides
RethinkPeptides Research Database. "Epitope-Specific Immunotherapy Targeting CD4-Positive T Cell..." RPEP-03262. Retrieved from https://rethinkpeptides.com/research/daveson-2017-epitopespecific-immunotherapy-targeting-cd4positive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.